RT Journal Article
T1 A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
A1 Gudiol, Carlota
A1 Arnan, Montserrat
A1 Aguilar-Guisado, Manuela
A1 Royo-Cebrecos, Cristina
A1 Sanchez-Ortega, Isabel
A1 Montero, Isabel
A1 Martin-Gandul, Cecilia
A1 Laporte-Amargos, Julia
A1 Albasanz-Puig, Adaia
A1 Nicolae, Sermed
A1 Perayre, Maria
A1 Berbel, Damaris
A1 Tebe, Cristian
A1 Riera, Judith
A1 Sureda, Anna
A1 Cisneros, Jose Miguel
A1 Carratala, Jordi
K1 antibiotic lock technique
K1 cancer
K1 catheter infection
K1 catheter-related bacteremia
K1 catheter-related bloodstream infection
K1 lock technique
K1 neutropenia
K1 prevention
K1 taurolidine
AB Infection of long-term central venous catheters (CVCs) remains a challenge in the clinical management of cancer patients. We aimed to determine whether a lock solution with taurolidine-citrate-heparin would be more effective than placebo for preventing nontunneled CVC infection in high-risk neutropenic hematologic patients. We performed a prospective, multicenter, randomized (1:1), double-blind, parallel, superiority, placebo-controlled trial involving 150 hematological patients with neutropenia carrying nontunneled CVCs who were assigned to receive CVC lock solution with taurolidine-citrate-heparin or heparin alone. The primary endpoint was bacterial colonization of the CVC hubs. Secondary endpoints were the incidence of catheter-related bloodstream infection (CRBSI), CVC removal, adverse events related to the lock solution, and the 30-day case fatality rate. CVC lock solution with taurolidine-citrate-heparin was associated with less colonization of the CVC hubs than that with placebo, with no statistically significant differences: 4.1%, versus 10.1% (relative risk [RR] = 0.41, 95% confidence interval [CI] = 0.11 to 1.52), with a cumulative incidence of 4.17 (95% CI = 0.87 to 11.70) and 10.14 (95% CI = 4.18 to 19.79), respectively. There were no significant differences regarding the secondary endpoints. Only three episodes of CRBSI occurred during the study period. No adverse events related to the administration of the lock solution occurred. In this trial involving high-risk patients carrying nontunneled CVCs, the use of taurolidine-citrate-heparin did not show a benefit over the use of placebo. Nevertheless, the safety of this prevention strategy and the trend toward less hub colonization in the taurolidine-citrate-heparin group raise the interest in assessing its efficacy in centers with higher rates of CRBSI. (This study has been registered in ISRCTN under identifier ISRCTN47102251.).
PB American Society for Microbiology
YR 2020
FD 2020-01-27
LK http://hdl.handle.net/10668/14671
UL http://hdl.handle.net/10668/14671
LA en
NO Gudiol C, Arnan M, Aguilar-Guisado M, Royo-Cebrecos C, Sánchez-Ortega I, Montero I, et al.  A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01521-19.
NO We thank the Bellvitge University Hospital Research Committee for the research grant awarded in 2012 and the nursing staff of the hematology departments. We thank CERCA Programme/Generalitat de Catalunya for institutional support.The TAURCAT study was a noncommercial, investigator-driven clinical trial funded by the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III (ISCIII) (grant PI13/01474), and the Spanish Network for Research in Infectious Diseases (REIPI; grant RD12/0015/0010), ISCIII, and by the Ministry of Economy, Industry and Competitiveness, cofinanced by European Development Regional Fund (A way to achieve Europe, Operational Program Intelligent Growth 2014-2020). The study also received an unrestricted grant from Bionet Medical S.L.Bionet Medical S.L. did not have any kind of involvement in the study.
DS RISalud
RD Apr 19, 2025